Fasenra pen 30 MG/mlml
Ended Awarded Last action
- Contract number
- SPE2DR26FDJR4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $2,494
Award facts
- Contract value 100% obligated
- $2,493.75 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $2,493.75 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for FASENRA Pen 30 mg/mL. The delivery order, issued on January 29, 2026, with an ultimate completion date of January 30, 2026, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (SPE2DR) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy that authorizes the issuance of firm fixed-price delivery orders for comprehensive pharmaceutical products and medical consumables to support Department of Defense military healthcare facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, with substantial contracting activity through numerous delivery orders issued by the Defense Logistics Agency's Medical Supply Chain division. The company's extensive product portfolio encompasses branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables, positioning it to fulfill the diverse pharmaceutical requirements of military healthcare operations. The PPV-G GEN V contract, awarded on November 13, 2025, with a ceiling value of $499,999,999 and completion date of December 31, 2036, features a 30-month base period with three 30-month option periods, enabling DMS Pharmaceutical Group to serve as a principal regional pharmaceutical supplier for global Department of Defense medical operations.
Quick answers
Who was awarded contract SPE2DR26FDJR4?
SPE2DR26FDJR4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 29, 2026.
How much is contract SPE2DR26FDJR4 worth?
The government has obligated $2,494 on SPE2DR26FDJR4.
Is contract SPE2DR26FDJR4 an order under another contract?
Yes. SPE2DR26FDJR4 is a delivery order under SPE2DR25D9144, an indefinite delivery contract.
Was contract SPE2DR26FDJR4 competed?
The extent of competition for SPE2DR26FDJR4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award